Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update

          Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides UpdateJune 17, 2025 9:00 AM EDT | Source: Thiogenesis Therapeutics, Corp.San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric and inherited mitochondrial diseases, today announced the recent activation o ...